| Literature DB >> 23092894 |
Vattoly J Majo1, Jaya Prabhakaran, J John Mann, J S Dileep Kumar.
Abstract
Radioligands for PET imaging of glutamate receptors will have the potential for studying neurological and neuropsychiatric disorders and their diagnosis and therapeutic intervention. Glutamate is the major excitatory neurotransmitter in the brain and is implicated in the pathophysiology of many neurodegenerative and neuropsychiatric disorders. Glutamate and its receptors are potential targets in the treatment of these disorders. Glutamate signaling is mediated through ionotropic and metabotropic receptors. The abundant concentration of these receptors can facilitate their in vivo quantification using positron emission tomography (PET). Glutamate receptors are a potentially important set of targets for monitoring disease progression, for evaluating the effect of therapy and for new treatment development based on the quantification of receptor occupancy. Here, we review the PET and single-photon emission computed tomography (SPECT) radioligands that have been developed for imaging glutamate receptors in living brain.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23092894 DOI： 10.1016/j.drudis.2012.10.004
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851